Pricing Log in Create free account
Saturday 17 October 2026 Export NTBLQ’s income statement to Excel — free account

Notable Labs, Ltd.

NTBLQ Healthcare Biotechnology

Revenue growth for three consecutive years.

0.00 0.00 NaN
Market cap
$2.4M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
2/9
Altman Z
−6.73
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 45.33%

Capital & Financial Ratios $m

Market Cap 2.39
Revenue (0.17)
Net Income (10.54)
Free Cash Flow (15.20)
Net Debt (3.87)
Current Ratio 2.77 (at or above 1.5: strong)
Debt/Equity 0.03 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.23) (negative: loss-making)
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 28.74% (at or above 15%: strong)
Next Y EPS Growth (46.50%) (below 0%: weak)
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 23.3×, against a ten-year median of 23.3×; over the ten years it ranged from −2,420× in 2023 to 433× in 2023.
EV/Sales against its own 10 years 57.47%
10-year low 10-year high
EV/FCF against its own 10 years 61.84%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2021 2022 2023 Q'24
Cash 53 2 12 4
Receivables — — — —
Inventory — — — —
Other 2 1 4 3
55 3 15 7
2021 2022 2023 Q'24
Payables 9 1 2 1
ST’ Debt — — — —
Other — — — —
10 2 3 3

Compound Annual Growth %

10y 5y 3y
Sales — (11.93%) (30.46%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (22.22%) (21.22%)

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’23 — — — — 0
’22 0 0 0 — 0
’21 0 0 0 0 1
’20 0 0 0 0 1
’19 0 0 0 0 1
’18 0 0 0 0 1
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’23 (3) (3) (2) (6) (14)
’22 (8) (10) (7) 13 (12)
’21 (6) (5) (7) (7) (25)
’20 (6) (7) (4) (7) (23)
’19 (3) (2) (4) (4) (13)
’18 (4) (5) (4) (3) (16)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’23 (3) (3) 6 (14) (14)
’22 (9) (10) (7) 14 (12)
’21 (6) (6) (7) (7) (26)
’20 (6) (7) (4) (7) (23)
’19 (3) (2) (4) (4) (13)
’18 (5) (5) (5) (3) (18)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.42) (0.55) — — —
’23 (6.46) (3.54) — 7.07 (3.41)
’22 (4.55) (4.20) (4.20) (1.75) (21.96)
’21 (4.20) (4.20) (3.15) (4.20) (15.73)
’20 (5.24) (4.90) (4.20) (5.24) (19.23)
’19 (4.20) (4.55) (4.90) (5.59) (18.88)
’18 (8.39) (4.55) (5.24) (3.50) (21.68)
Fiscal quarters ending in the months shown.
value withheld pending a data check

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Trend 2024e 2025e 2026e
Price, $
Price, $ Low — — 96.60 136.50 21.00 32.55 31.50 57.75 3.54 1.82

Analyst estimates 2024–2026

Powerpack
High — — 265.30 316.75 306.25 66.50 72.10 110.95 77.00 11.20
People
People Employees — — 34 37 39 38 38 41 7 16
Revenue/emp, $m — — 0.00 0.37 0.02 0.01 0.02 0.02 0.00 0.02
Income, $m
Income, $m Revenue — — — 14 1 1 1 1 0 0
Gross margin, % — — 0.00 97.55 59.83 60.50 57.27 52.47 100.00 36.45
EBT — — (16) (10) (20) (19) (24) (30) (14) (11)
EBT margin, % — — 0.00 (73.12) (3,497.09) (3,451.25) (2,627.44) (3,895.83) (180,087.50) (3,633.55)
Net income — — (16) (10) (20) (19) (24) (30) (14) (11)
Depreciation — — 0 0 1 1 1 1 0 0
Per share, $
Per share, $ Revenue — — 0.00 17.69 0.62 0.55 0.74 0.40 0.01 0.09
Earnings — — (22.38) (12.94) (21.68) (18.88) (19.23) (15.73) (21.96) (3.41)
Cash flow — — (18.78) (4.88) (16.63) (12.75) (18.72) (13.17) (17.75) (4.15)
Capex — — (0.69) (8.27) (2.36) (0.07) (0.04) (0.77) 0.08 (0.02)
Free cash flow — — (19.47) (13.15) (18.99) (12.83) (18.76) (13.94) (17.66) (4.17)
Book value — — 59.37 71.34 56.31 35.10 24.76 26.66 (56.35) 4.58
Shares, m — — 1 1 1 1 1 2 1 3
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 0.00 54.72 76.69 89.60 170.36 387.86 759.69
P/B — — — 3.53 0.60 1.20 2.67 2.59 0.00 0.40
EV/Sales — — — 0.00 (30.81) 11.86 58.74 103.52 363.86 (685.56)
EV/FCF — — — (13.85) 1.01 (0.51) (2.31) (3.01) (0.25) 0.40
Cash, $m
Cash, $m Operating cash flow — — (13) (4) (16) (13) (23) (25) (12) (14)
Capex — — 0 (6) (2) 0 0 (1) 0 0
Free cash flow — — (14) (10) (18) (13) (23) (26) (12) (14)
Balance, $m
Balance, $m Working capital — — 42 51 47 29 25 45 1 13
Total debt — — — — 0 0 2 2 1 0
Net debt — — (45) (55) (50) (36) (28) (51) (2) (12)
Shareholders’ equity — — 42 56 53 36 31 51 (37) 15
Returns, %
Returns, % ROA — — (36.99) (17.95) (32.38) (35.37) (53.41) (56.26) (41.06) (89.92)
ROIC — — 0.00 (568.69) (433.15) 0.00 (611.83) 0.00 0.00 (257.90)
ROE — — (41.35) (20.63) (37.54) (43.53) (72.38) (73.43) (211.68) 103.08
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Jun 2024

Charts ten years each

Notable Labs, Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EIGRQ Eiger BioPharmaceuticals, Inc. $2.6M — (loss-making) — (loss-making) +41.06% (above 0%: growing) n/m +37.90% (above 0%: growing) 97.34% (331.69%) Compare
BIORQ Biora Therapeutics, Inc. $2.5M — (loss-making) — (loss-making) +1,500.00% (above 0%: growing) n/m +20.72% (above 0%: growing) 100.00% (50,709.38%) Compare
ELAB PMGC Holdings Inc. $2.5M — (loss-making) — +147.70% (above 0%: growing) n/m −44.95% (below 0%: shrinking) 29.52% (292.91%) Compare
NTBLQ Notable Labs, Ltd. $2.4M — (loss-making) — (loss-making) −96.88% (below 0%: shrinking) n/m −26.63% (below 0%: shrinking) 100.00% (269,000.00%)
VBIO Valion Bio, Inc. $2.4M — (loss-making) — (loss-making) +15.87% (above 0%: growing) n/m −189.01% (below 0%: shrinking) (99.32%) 0.00% Compare
MTNB Matinas Biopharma Holdings, Inc. $2.4M — (loss-making) — (loss-making) +365,433.33% (above 0%: growing) n/m +9.15% (above 0%: growing) 0.00% 0.00% Compare
BPTSY Biophytis SA Sponsored ADR $2.4M — (loss-making) — — n/m +53.15% (above 0%: growing) 0.00% — Compare
WINT Windtree Therapeutics, Inc. $2.4M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m +1.12% (above 0%: growing) 0.00% 0.00% Compare
KAPA Kairos Pharma, Ltd. $2.3M — (loss-making) — — n/m −25.71% (below 0%: shrinking) — 0.00% Compare
Median of peers $2.4M — — +94.38% — +5.14% 0.00% 0.00%

All 614 Biotechnology stocks →

Notable Labs, Ltd. (NTBLQ) key facts

  • Notable Labs, Ltd. (NTBLQ) is a Biotechnology company in the Healthcare sector.
  • Return on equity was 103.1% and debt-to-equity 0.03.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −6.73 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.

Notable Labs, Ltd. (NTBLQ) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NTBLQ · Data as of Jun 30, 2024 · For information only; not investment advice. · © 2026 stockrow.com